| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WEREWOLF THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Werewolf Therapeutics weighs sale or merger as cash reserves whimper | 2 | FierceBiotech | ||
| Di | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives | 295 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of... ► Artikel lesen | |
| 13.02. | Werewolf Therapeutics streicht 64 % der Stellen - Aktie gibt nach | 4 | Investing.com Deutsch | ||
| 06.02. | Werewolf Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.12.25 | H.C. Wainwright senkt Kursziel für Werewolf Therapeutics nach Pipeline-Update drastisch | 17 | Investing.com Deutsch | ||
| 19.12.25 | H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update | 3 | Investing.com | ||
| 18.12.25 | Werewolf Therapeutics reports 30% response rate for WTX-124 in melanoma patients | 1 | Investing.com | ||
| 18.12.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
| 04.11.25 | Werewolf Therapeutics reports Q3 results | 10 | Seeking Alpha | ||
| 04.11.25 | Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.11.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.10.25 | Werewolf Therapeutics Says FDA Grants Fast Track For WTX-124 In Advanced Melanoma Treatment | 4 | RTTNews | ||
| 08.10.25 | Werewolf Therapeutics receives FDA Fast Track for melanoma therapy | 3 | Investing.com | ||
| 08.10.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | 376 | GlobeNewswire (Europe) | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| 06.10.25 | Todesfall im Verwaltungsrat: Werewolf Therapeutics erfüllt NASDAQ-Regeln für Prüfungsausschuss nicht mehr | 8 | Investing.com Deutsch | ||
| 06.10.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.10.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 08.05.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 416 | GlobeNewswire (Europe) | - WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking... ► Artikel lesen | |
| 17.04.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer | 501 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,00 | -0,32 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| EVOTEC | 5,720 | -2,36 % | Evotec: Das Biotech-Drama geht in die nächste Runde | Die Aktie des Hamburger Wirkstoffforschers Evotec versucht erneut den Befreiungsschlag, doch das Misstrauen am Markt ist greifbar. Nach einer beispiellosen Serie von Rückschlägen - von Management-Skandalen... ► Artikel lesen | |
| BB BIOTECH | 51,70 | +0,58 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| MEDIGENE | 0,036 | -10,00 % | Medigene: Zurückziehung - 18.11.2025 | ||
| MODERNA | 44,410 | -2,06 % | Moderna's combination flu, COVID shot wins over European drug regulators | ||
| VALNEVA | 4,626 | -2,20 % | Valneva-Aktie: Die letzte Chance | Für den französischen Impfstoffentwickler Valneva entscheidet sich 2026 ein großer Teil der Investmentstory. Die Aktie wird derzeit fast ausschließlich durch die Erwartung der Phase-3-Daten zum Lyme-Borreliose-Impfstoff... ► Artikel lesen | |
| NOVAVAX | 8,350 | -2,66 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 162,75 | +0,25 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,800 | -4,31 % | Crispr Therapeutics gains amid takeover speculation | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,385 | -1,53 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,100 | -5,51 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| INFLARX | 0,785 | +0,77 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| BAVARIAN NORDIC | 25,820 | -1,90 % | Bavarian Nordic A/S: Paul Chaplin Steps Down as CEO of Bavarian Nordic | COPENHAGEN, Denmark, March 2, 2026 - Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal... ► Artikel lesen |